4 ms·
Participate in a Phase IV trial at your peril. But I wonder whether I'd say the same if I hadn't learned to lose and keep off all the weight I needed to, befor
by throwanem 2y ago
Participate in a Phase IV trial at your peril.
But I wonder whether I'd say the same if I hadn't learned to lose and keep off all the weight I needed to, before it came along.
(If the downvotes are because I sound like I'm bragging, that's fair but also not my intent. What I mean to say is, I suspect I'd view this class of drug and indication less dispassionately and with more of an appetite for risk, if I weren't so lucky as to have no pressing need for the benefit.)
- ebiester 2y agoYes, but we've had Ozempic since 2017 for type 2 diabetes. That's longer than Vioxx was on the market.
- WillPostForFood 2y agoAnd other GLP-1 receptor agonists since 2005 when Exenatide was approved.
- cyberax 2y agoAnd before that, liraglutide. Ozempic (semaglutide) is basically the same drug with some tweaks to extend its half-life.
- throwanem 2y agoGranted, although I might counter that given so broad an apparent increase in the scope of the indication, 2017-2021 (? I can't immediately find a date for Ozempic specifically) and 2021- might best be taken as at least partially distinct. I think that's an argument less well advanced by me than by someone who could design such a study, though, not least because they'll know far better than I whether the proposition makes any real sense.